Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Other Non Operating Income (2020 - 2025)

Lyell Immunopharma's Other Non Operating Income history spans 5 years, with the latest figure at -$4.9 million for Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 11200.0% year-over-year to -$4.9 million; the TTM value through Sep 2025 reached $1.9 million, up 1949.04%, while the annual FY2024 figure was $4.7 million, 154.28% up from the prior year.
  • Other Non Operating Income for Q3 2025 was -$4.9 million at Lyell Immunopharma, down from $1.2 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $4.3 million in Q4 2024 and bottomed at -$4.9 million in Q3 2025.
  • The 5-year median for Other Non Operating Income is -$14000.0 (2022), against an average of $310368.4.
  • The largest annual shift saw Other Non Operating Income soared 6768.18% in 2022 before it plummeted 11200.0% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$44000.0 in 2021, then skyrocketed by 6768.18% to $2.9 million in 2022, then tumbled by 117.25% to -$506000.0 in 2023, then skyrocketed by 948.22% to $4.3 million in 2024, then plummeted by 213.21% to -$4.9 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Other Non Operating Income are -$4.9 million (Q3 2025), $1.2 million (Q2 2025), and $1.3 million (Q1 2025).